EISAI CO
- Country
- 🇯🇵Japan
- Ownership
- Public
- Established
- 1941-12-06
- Employees
- 11K
- Market Cap
- $12B
- Website
- http://www.eisai.co.jp
A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2016-12-30
- Last Posted Date
- 2023-12-13
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 104
- Registration Number
- NCT03006926
- Locations
- 🇺🇸
Mercy Medical Center, Baltimore, Maryland, United States
🇺🇸Ronald Reagan UCLA Medical Center, Santa Monica, California, United States
🇺🇸Icahn School of Medicine Mount Sinai, New York, New York, United States
Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors
- First Posted Date
- 2016-12-30
- Last Posted Date
- 2021-05-20
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT03006887
- Locations
- 🇯🇵
Eisai Trial Site 1, Chuo-ku, Tokyo, Japan
A Trial of Lenvatinib (E7080) in Radioiodine (131 I)-Refractory Differentiated Thyroid Cancer in China
- Conditions
- Interventions
- First Posted Date
- 2016-11-17
- Last Posted Date
- 2022-01-26
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 151
- Registration Number
- NCT02966093
- Locations
- 🇨🇳
1025 Eisai Trial Site, Xiamen, Fujian, China
🇨🇳1003 Eisai Trial Site, Guangzhou, Guangdong, China
🇨🇳1006 Eisai Trial Site, Beijing, Beijing, China
A Dose Response Study of E6011 in Participants With Rheumatoid Arthritis Inadequately Responding to Methotrexate
- First Posted Date
- 2016-11-09
- Last Posted Date
- 2021-06-21
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 273
- Registration Number
- NCT02960438
- Locations
- 🇯🇵
Eisai Trial Site #1, Shizuoka, Japan
🇯🇵Eisai Trial Site #4, Nagoya, Aichi, Japan
🇯🇵Eisai Trial site #2, Hyuga, Miyazaki, Japan
A Phase 2 Study of E6011 in Subjects With Rheumatoid Arthritis Inadequately Responding to Biologics
- First Posted Date
- 2016-11-09
- Last Posted Date
- 2021-08-23
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 66
- Registration Number
- NCT02960490
- Locations
- 🇯🇵
Eisai Trial Site #3, Nagasaki, Japan
🇯🇵Eisai Trial Site #4, Fukuoka, Japan
🇯🇵Eisai Trial Site #1, Toyama, Japan
A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants With Early Alzheimer's Disease
- First Posted Date
- 2016-11-06
- Last Posted Date
- 2021-02-03
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 2212
- Registration Number
- NCT02956486
- Locations
- 🇯🇵
Eisai Trial Site 1, Osaka, Japan
🇬🇧Facility #1, London, United Kingdom
🇺🇸Facility #11, Miami, Florida, United States
Pharmacokinetic Study of E7080/Lenvatinib in Chinese Patients With Unresectable Hepatocellular Carcinoma (HCC)
- First Posted Date
- 2016-11-03
- Last Posted Date
- 2021-04-01
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 25
- Registration Number
- NCT02953743
- Locations
- 🇨🇳
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
🇨🇳Shanghai Cancer Hospital, Fudan University, Shanghai, Shanghai, China
🇨🇳Zhongshan Hospital Fudan University, Shanghai, Shanghai, China
Study to Evaluate the Effect of Diltiazem Extended Release on the Pharmacokinetics of E2027 in Healthy Subjects
- First Posted Date
- 2016-10-28
- Last Posted Date
- 2017-03-07
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT02947711
Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2016-02-08
- Last Posted Date
- 2021-07-15
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 45
- Registration Number
- NCT02676778
- Locations
- 🇯🇵
Eisai Trial Site #1, Okayama, Japan
🇯🇵Eisai Trial Site #2, Suita, Osaka, Japan
A Study of Donepezil Hydrochloride in Patients With Dementia Associated With Cerebrovascular Disease
- Conditions
- Interventions
- First Posted Date
- 2016-01-21
- Last Posted Date
- 2020-01-10
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 302
- Registration Number
- NCT02660983